Safe de-escalation of chemotherapy in HER2-positive early breast cancer.

Lancet

Department of Oncology, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address:

Published: April 2024

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(24)00535-XDOI Listing

Publication Analysis

Top Keywords

safe de-escalation
4
de-escalation chemotherapy
4
chemotherapy her2-positive
4
her2-positive early
4
early breast
4
breast cancer
4
safe
1
chemotherapy
1
her2-positive
1
early
1

Similar Publications

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Nat Cancer

January 2025

Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Cancer Cluster Salzburg, Salzburg, Austria.

The role of anthracyclines in the treatment of early breast cancer (EBC) is increasingly being challenged, especially in de-escalation strategies. However, owing to their immunogenic effects, anthracyclines are promising combination partners with immunotherapies. In the randomized phase 2 trial ABCSG-52 (EudraCT no.

View Article and Find Full Text PDF

Introduction: Children and adolescents with neurodevelopmental and psychiatric comorbidities, particularly autism spectrum disorder and developmental delays (ASD/DD), present unique challenges in pediatric emergency department (PED) settings. Youths with ASD/DD are prone to sensory overload and frequently exhibit agitation and/or aggression, necessitating specialized interventions. However, PEDs lack standardized protocols for managing behavioral dysregulation in this vulnerable population, often relying on anecdotal treatment approaches that hinder the provision of safe, effective and individualized care.

View Article and Find Full Text PDF

The use of temporary left ventricular assist devices (tLVADs) for patients suffering from cardiogenic shock (CS) is becoming more common. This study examines the indications and outcomes of microaxial flow pumps (Impella, Abiomed Inc., Danvers, MA, USA) when cannulated through the axillary artery in patients with severe CS, with a particular focus on acute phase reactions and hemolytic responses.

View Article and Find Full Text PDF

Virtual Reality Training to Reduce Workplace Violence in Healthcare.

Issues Ment Health Nurs

January 2025

Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia, USA.

Violence against nurses and other healthcare workers is a significant and escalating concern, impeding the provision of safe and effective healthcare services. A majority of nurses experience some kind of violence, including physical and nonphysical assaults during their careers. The consequences of workplace violence extend beyond individual trauma, leading to increased burnout, turnover, and significant financial costs for healthcare systems.

View Article and Find Full Text PDF

Background: Anti-CD20 are among the high-efficacy DMTs commonly used in treating multiple sclerosis (MS). Long-term safety data on anti-CD20s are limited. There is convincing evidence of hypogammaglobulinemia in the long-term use of anti-CD20s, raising the likelihood of infection.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!